A5023897070- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Uterine Myomas and Treatments
- Endometriosis Research and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Reproductive Biology and Fertility
- Organ and Tissue Transplantation Research
- BRCA gene mutations in cancer
- PARP inhibition in cancer therapy
- Pelvic floor disorders treatments
- MicroRNA in disease regulation
- Colorectal and Anal Carcinomas
- Cervical Cancer and HPV Research
- Gynecological conditions and treatments
- Minimally Invasive Surgical Techniques
- Reproductive System and Pregnancy
- Sperm and Testicular Function
- Testicular diseases and treatments
- Lung Cancer Research Studies
- Renal and related cancers
- Lung Cancer Treatments and Mutations
- Circular RNAs in diseases
- Extracellular vesicles in disease
- Sarcoma Diagnosis and Treatment
- Organ Donation and Transplantation
Università degli Studi di Enna Kore
2023-2025
Ospedale Cannizzaro
2016-2025
Advanced Neural Dynamics (United States)
2024
New York Proton Center
2023
Clarke University
2023
Box (United States)
2023
Sapienza University of Rome
2022
Policlinico Umberto I
2022
University of Catania
2006-2014
Università Cattolica del Sacro Cuore
2006-2007
Uterus transplantation (UTx) is a novel type of to treat infertility in women with an absent or nonfunctioning uterus. The International Society Transplantation (ISUTx) has developed registry monitor worldwide UTx activities while serving as repository for specific research questions.The web-based separate data fields donor, recipient, surgeries, immunosuppression, rejections, pregnancies live birth(s), and transplant hysterectomies. Data are prospectively registered.A total 45 procedures...
Ovarian cancer (OvC) constitutes significant management challenges primarily due to its late-stage diagnosis and the development of resistance chemotherapy. The standard treatment regimen typically includes carboplatin paclitaxel, with addition poly (ADP-ribose) polymerase inhibitors for patients high-grade serous ovarian (HGSOC) harboring BRCA1/2 mutations. However, variability in responses suggests need investigate factors beyond mutations, such as DNA repair mechanisms epigenetic...
Neoadjuvant chemotherapy may represent an alternative to irradiation in locally advanced squamous cell cervical cancer. Aims of this study were compare a three-drug (paclitaxel, ifosfamide, and cisplatin [TIP]) with two-drug (ifosfamide [IP]) regimen assess the prognostic value pathologic response on survival.Patients (n = 219) randomly assigned ifosfamide 5 g/m(2) during 24 hours plus 75 mg/m(2), or paclitaxel 175 mg/m(2) every 3 weeks for three courses.Grades 4 neutropenia, anemia,...
In this study, for the first time, we demonstrated presence of microRNAs and extracellular vesicles in human blastocoel fluid. The bioinformatic comparative analyses identified biological function fluid suggested a potential role inside blastocyst. We found 89 microRNAs, expressed at different levels, able to regulate critical signaling pathways controlling embryo development, such as pluripotency, cell reprogramming, epigenetic modifications, intercellular communication, adhesion fate....
Although a surgical approach is one of the key treatments for stages IA1-IIA2, results Laparoscopic Approach to Cervical Cancer (LACC) published in 2018 radically changed field, since minimally invasive surgery was associated with four-fold higher rate recurrence and six-fold all-cause death compared an open approach. We aimed evaluate outcomes abdominal radical hysterectomy (ARH) total laparoscopic (TLRH) cervical cancer, including data collected before LACC trial. In our retrospective...
Ovarian cancer recurs in most patients, with a 5-year survival rate less than 30%. Quality of life is an increasingly important issue patients cancer, but there are limited data women recurrent ovarian this regard.We used ad hoc questionnaire to compare changes health perceptions, burden disease, and expectations for the future quality without recurrence cancer. A total 173 were included, 116 relapse 57 without, undergoing follow-up routine clinical setting.Substantial differences seen...
Maternal RNAs are synthesized by the oocyte during its growth; some of them utilized for oocyte-specific processes and metabolism, others stored used early development before embryonic genome activation. The appropriate expression complex sets genes is needed maturation embryo development. In spite basic role noncoding in regulation gene expression, few studies have analyzed their human oocytes. this study, we identified microRNAs (miRNAs) expressed metaphase II stage oocytes, found that...
Ovarian aging affects female reproductive potential and is characterized by alterations in proteins, mRNAs non-coding RNAs inside the ovarian follicle. somatic cells oocyte communicate with each other secreting different molecules into follicular fluid, extracellular vesicles. The cargo of fluid vesicles may influence ability; accordingly, analysis vesicle content could provide information about quality germ cell.In order to identify most significant deregulated microRNAs aging, we...
Borderline ovarian tumors (BOTs) comprise 15–20% of primary neoplasms and represent an independent disease entity among epithelial cancers. The present study (Clinical Trial ID: NCT05791838) aimed to report a retrospective analysis the management outcomes 86 consecutive BOTs patients, 54 which were at reproductive age. All patients with undergoing surgical treatment from January 2010 December 2017 included. Data retrospectively reviewed. High levels Ca-125 observed in 25.6% FIGO stage I...
In recent years, generative Artificial Intelligence models, such as ChatGPT, have increasingly been utilized in healthcare. Despite acknowledging the high potential of AI models terms quick access to sources and formulating responses a clinical question, results obtained using these still require validation through comparison with established guidelines. This study compares model eight questions Italian Association Medical Oncology (AIOM) guidelines for ovarian cancer.
PURPOSE Lenvatinib plus pembrolizumab (len + pembro) significantly improved progression-free survival (PFS) and overall (OS) versus chemotherapy in previously treated advanced or recurrent endometrial cancer (aEC) the phase III Study 309/KEYNOTE-775. We report results from III, randomized, open-label European Network of Gynaecological Oncological Trial-en9/LEAP-001 study (ClinicalTrials.gov identifier: NCT03884101 ) that evaluated len pembro first-line aEC. METHODS Patients with stage to IV...